NZ549976A - Naltrexone long acting formulations and methods of use - Google Patents

Naltrexone long acting formulations and methods of use Download PDF

Info

Publication number
NZ549976A
NZ549976A NZ549976A NZ54997605A NZ549976A NZ 549976 A NZ549976 A NZ 549976A NZ 549976 A NZ549976 A NZ 549976A NZ 54997605 A NZ54997605 A NZ 54997605A NZ 549976 A NZ549976 A NZ 549976A
Authority
NZ
New Zealand
Prior art keywords
naltrexone
long acting
administered
individual
acting formulation
Prior art date
Application number
NZ549976A
Other languages
English (en)
Inventor
Elliot Ehrich
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35187918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ549976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of NZ549976A publication Critical patent/NZ549976A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ549976A 2004-04-22 2005-03-18 Naltrexone long acting formulations and methods of use NZ549976A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56454204P 2004-04-22 2004-04-22
US11/083,167 US7919499B2 (en) 2004-04-22 2005-03-17 Naltrexone long acting formulations and methods of use
PCT/US2005/009133 WO2005107753A2 (en) 2004-04-22 2005-03-18 Naltrexone long acting formulations and methods of use

Publications (1)

Publication Number Publication Date
NZ549976A true NZ549976A (en) 2009-11-27

Family

ID=35187918

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ549976A NZ549976A (en) 2004-04-22 2005-03-18 Naltrexone long acting formulations and methods of use

Country Status (10)

Country Link
US (5) US7919499B2 (https=)
EP (2) EP2386269A3 (https=)
JP (2) JP5426094B2 (https=)
KR (2) KR20070005722A (https=)
CN (1) CN103251597A (https=)
AU (1) AU2005239989B2 (https=)
CA (1) CA2563086C (https=)
NZ (1) NZ549976A (https=)
RU (1) RU2370257C2 (https=)
WO (1) WO2005107753A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2818973B2 (ja) 1990-10-22 1998-10-30 株式会社藤井鉄工所 スキップ式水路用スクリーン除塵機
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
RU2471478C1 (ru) * 2011-12-08 2013-01-10 Станислав Анатольевич Кедик Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона
WO2016160715A1 (en) * 2015-03-27 2016-10-06 Markel Dan Method for treating addiction
AU2019362730B2 (en) 2018-10-15 2022-10-20 Chong Kun Dang Pharmaceutical Corp. Injectable long-acting naltrexone microparticle compositions
KR102898979B1 (ko) 2018-12-27 2025-12-10 에일러 파마슈티컬스 아이엔씨. 주사가능한 날트렉손 서방형 약학 제제
GR1009871B (el) * 2019-07-30 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου
US12343340B2 (en) 2020-12-31 2025-07-01 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11752143B2 (en) 2020-12-31 2023-09-12 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11197819B1 (en) 2021-04-09 2021-12-14 Drug Delivery Company, Llc Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system
AU2022202053A1 (en) 2021-09-17 2023-04-06 Biocorrx, Inc. Biodegradable implant including naltrexone
WO2023114557A2 (en) * 2021-12-17 2023-06-22 Journey Colab Corp. METHODS OF TREATING SUBSTANCE USE DISORDERS USING 5-MeO-DMT
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719219A (en) 1982-03-30 1988-01-12 Per A. E. Carlsson Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
RO121631B1 (ro) 1999-08-27 2008-01-30 Southern Research Institute Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool
WO2001043726A1 (en) 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
NZ540318A (en) 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
CN1166360C (zh) * 2002-11-07 2004-09-15 上海医药工业研究院 一种纳曲酮长效注射微球组合物及制备方法和应用
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7279579B2 (en) 2003-06-04 2007-10-09 Alkermes, Inc. Polymorphic forms of naltrexone

Also Published As

Publication number Publication date
CN103251597A (zh) 2013-08-21
EP2386269A2 (en) 2011-11-16
JP2011225600A (ja) 2011-11-10
US20050245558A1 (en) 2005-11-03
KR20070005722A (ko) 2007-01-10
US20140155424A1 (en) 2014-06-05
WO2005107753A3 (en) 2005-12-29
AU2005239989B2 (en) 2008-05-29
JP5426094B2 (ja) 2014-02-26
EP1740120A4 (en) 2008-06-25
CA2563086A1 (en) 2005-11-17
RU2006137349A (ru) 2009-04-20
WO2005107753A2 (en) 2005-11-17
JP2007533738A (ja) 2007-11-22
KR20090050111A (ko) 2009-05-19
US20110212985A1 (en) 2011-09-01
EP2386269A3 (en) 2012-04-25
AU2005239989A1 (en) 2005-11-17
US7919499B2 (en) 2011-04-05
CA2563086C (en) 2018-04-17
US20210244818A1 (en) 2021-08-12
RU2370257C2 (ru) 2009-10-20
US20180064814A1 (en) 2018-03-08
EP1740120A2 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
US20210244818A1 (en) Naltrexone Long Acting Formulations and Methods of Use
Davids et al. Buprenorphine in the treatment of opioid dependence
AU780852B2 (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
EP1212061B1 (en) Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol
CN108743549B (zh) 活性药物成分的自调节释放
US7041320B1 (en) High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US11000479B2 (en) Injectable long-acting naltrexone microparticle compositions
RU2471478C1 (ru) Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона
RU2817016C2 (ru) Инъекционные композиции микрочастиц налтрексона длительного действия
CN1946353B (zh) 纳曲酮长效制剂和使用方法
EP1555023A2 (en) Injectable buprenorphine microparticle compositions and their use
Lin Buprenorphine microspheres: Formulations, dissolution, and subcutaneous absorption

Legal Events

Date Code Title Description
PSEA Patent sealed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150303

ASS Change of ownership

Owner name: ALKERMES PHARMA IRELAND LIMITED, IE

Effective date: 20151029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240229

EXPY Patent expired